Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats

Authors

  • Charles W Schindler,

    Corresponding author
    1. Preclinical Pharmacology, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA
    • Correspondence

      Charles W Schindler, Preclinical Pharmacology, National Institutes of Health/National Institute on Drug Abuse, 251 Bayview Blvd, Suite 200, Baltimore, MD 21224, USA. E-mail: cschind@helix.nih.gov

    Search for more papers by this author
  • Eric B Thorndike,

    1. Preclinical Pharmacology, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA
    Search for more papers by this author
  • Bruce E Blough,

    1. RTI International, Research Triangle Park, NC, USA
    Search for more papers by this author
  • Srihari R Tella,

    1. Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Springfield, VA, USA
    Search for more papers by this author
  • Steven R Goldberg,

    1. Preclinical Pharmacology, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA
    Search for more papers by this author
  • Michael H Baumann

    1. Medicinal Chemistry Section, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA
    Search for more papers by this author

Abstract

Background and Purpose

The cardiovascular effects produced by 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) contribute to its acute toxicity, but the potential role of its metabolites in these cardiovascular effects is not known. Here we examined the effects of MDMA metabolites on cardiovascular function in rats.

Experimental Approach

Radiotelemetry was employed to evaluate the effects of s.c. administration of racemic MDMA and its phase I metabolites on BP, heart rate (HR) and locomotor activity in conscious male rats.

Key Results

MDMA (1–20 mg·kg−1) produced dose-related increases in BP, HR and activity. The peak effects on HR occurred at a lower dose than peak effects on BP or activity. The N-demethylated metabolite, 3,4-methylenedioxyamphetamine (MDA), produced effects that mimicked those of MDMA. The metabolite 3,4-dihydroxymethamphetamine (HHMA; 1–10 mg·kg−1) increased HR more potently and to a greater extent than MDMA, whereas 3,4-dihydroxyamphetamine (HHA) increased HR, but to a lesser extent than HHMA. Neither dihydroxy metabolite altered motor activity. The metabolites 4-hydroxy-3-methoxymethamphetamine (HMMA) and 4-hydroxy-3-methoxyamphetamine (HMA) did not affect any of the parameters measured. The tachycardia produced by MDMA and HHMA was blocked by the β-adrenoceptor antagonist propranolol.

Conclusions and Implications

Our results demonstrate that HHMA may contribute significantly to the cardiovascular effects of MDMA in vivo. As such, determining the molecular mechanism of action of HHMA and the other hydroxyl metabolites of MDMA warrants further study.

Ancillary